论文部分内容阅读
目的观察替吉奥胶囊(S-1)联合奥沙利铂方案治疗晚期胃癌的临床疗效及不良反应。方法 42例晚期胃癌患者采用联合化疗:替吉奥胶囊每天80mg/m2,分2次,餐后口服,d1~14;奥沙利铂130mg/m2,静脉滴注3h,d1;28d为1个周期。结果 CR3例(7.1%),PR17例(40.5%),SD12例(28.6%),PD10例(23.8%),CR+PR(47.6%)。不良反应主要是骨髓抑制,胃肠道反应及外周神经毒性。结论替吉奥胶囊(S-1)联合奥沙利铂方案治疗晚期胃癌的近期疗效较好,不良反应可以耐受,可改善患者的生存质量。
Objective To observe the clinical efficacy and adverse reactions of tigeo capsule (S-1) and oxaliplatin regimen in the treatment of advanced gastric cancer. Methods Forty-two patients with advanced gastric cancer were treated with combination chemotherapy: Teglitazone 80mg / m2, twice daily, postprandial oral d1-14, oxaliplatin 130mg / m2, intravenous infusion 3h, d1 28d cycle. Results CR3 (7.1%), PR17 (40.5%), SD12 (28.6%), PD10 (23.8%) and CR + PR (47.6%). Adverse reactions are mainly myelosuppression, gastrointestinal reactions and peripheral neurotoxicity. Conclusion The short-term curative effect of G-1 combined with oxaliplatin in the treatment of advanced gastric cancer is good. Adverse reactions can be tolerated and the quality of life of the patients can be improved.